Over 55% of all malignancies occur in persons aged 65 years or older. Ageing brings about various physiological changes that can influence how cancer treatments work in the body and it underscores the need for tailored pharmacokinetic considerations in cancer treatment for older adults. Docetaxel has significant activity in solid malignancies, including breast, non-small cell lung, prostate, gastric and head and neck cancers. Despite its effectiveness, docetaxel is associated with several adverse effects. Management of side effects and the decision to use docetaxel, especially in older patients requires careful consideration and often involves premedication protocols to mitigate risks. Model-based dosing of chemotherapy agents throws light on patient-specific dosing, which tailors the dose of chemotherapeutic agents based on the unique characteristics of the patient. Population PK analysis has the potential to integrate all relevant PK information across a range of doses and populations to identify factors that can affect a drug’s exposure. These analyses, in turn, can inform strategies to select initial dosage regimens, manage dosing and administration for a given subpopulation, plan subsequent studies, or support labelling. Therefore, this study aims to create a popPK mathematical model for the dosing of Docetaxel tailored for the Indian elderly population.